Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis. J Manag Care Spec Pharm. 2018;24(4 suppl a):S70-S71.

https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.4-a.s1

Toth P, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database [abstract]. J Am Coll Cardiol. 2019;73:1744.

http://www.onlinejacc.org/content/73/9_Supplement_1/1744
Leatherman S, Ferguson R, Weir I, et al. Increased residual cardiovascular risk in US veterans and moderately-elevated baseline triglycerides and well-controlled LCL-C levels on statins [abstract]. J Am Coll Cardiol. 2019;73:1719. http://www.onlinejacc.org/content/73/9_Supplement_1/1719

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1445.

http://www.onlinejacc.org/content/71/11_Supplement/A1445

Pagidipati N, Navar A, Mulder H, Wojdyla DM, Philip S, Granowitz CB. Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trialDiabetes. 2019;68(suppl 1):1472P.

http://diabetes.diabetesjournals.org/content/68/Supplement_1/1472-P

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients. Vasc Health Risk Manag. 2019;15:533-538.

https://www.ncbi.nlm.nih.gov/pubmed/31824165

Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk By Statin Use In U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. Diabetes Care. 2019. [Epub ahead of print]

https://care.diabetesjournals.org/content/early/2019/09/27/dc19-0501

In Chronological Order

 

Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019; epub ahead of print. https://www.tandfonline.com/doi/full/10.1080/00325481.2019.1643633

https://www.ncbi.nlm.nih.gov/pubmed/31306043

Toth PP, Philip S, Hull M, Granowitz C. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patientsMayo Clin Proc. 2019;94(9):1670-1680.
https://www.mayoclinicproceedings.org/article/S0025-6196(19)30382-9/fulltext

https://www.ncbi.nlm.nih.gov/pubmed/31405751

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patientsCardiorenal Med. 2019.

https://www.ncbi.nlm.nih.gov/pubmed/31450229

Toth PP, Philip S, Hull M, Granowitz C. Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: A large administrative retrospective analysisClin Cardiol. 2019;1–6.

https://doi.org/10.1002/clc.23241

Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL cholesterolDiabetes Obes Metab. 2019;21:366-371.
https://www.ncbi.nlm.nih.gov/pubmed/30225881

https://onlinelibrary.wiley.com/doi/full/10.1111/dom.13537

Nichols GA, Philip S, Reynolds K, Granowitz CB, O’Keeffe-Rosetti M, Fazio S. Comparison of medical care utilization and costs among patients with statin-controlled LDL cholesterol with versus without hypertriglyceridemia. Am J Cardiol. 2018. Doi: 10.1016/j.amjcard.2018.06.029.  https://www.ajconline.org/article/S0002-9149(18)31321-3/fulltext

https://www.ajconline.org/article/S0002-9149(18)31321-3/fulltext

Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.

https://www.ahajournals.org/doi/10.1161/JAHA.118.008740
Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides
Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides [abstract]. Circulation. 2017;136(suppl 1):A15097.
copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation